Fairmount Funds Management LLC - 04 Dec 2025 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (GLYC)

Role
Director, 10%+ Owner
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Issuer symbol
GLYC
Transactions as of
04 Dec 2025
Net transactions value
+$19,999,999
Form type
4
Filing time
08 Dec 2025, 16:30:15 UTC
Previous filing
17 Nov 2025
Next filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (4)

Name Relationship Address Signature Signature date CIK
Fairmount Funds Management LLC Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 08 Dec 2025 0001802528
Fairmount Healthcare Fund II L.P. Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II, L.P. 08 Dec 2025 0001769651
Kiselak Tomas Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak 08 Dec 2025 0001830177
Harwin Peter Evan Director, 10%+ Owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Peter Harwin 08 Dec 2025 0001663607

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBIO Ordinary Shares Purchase $18,237,600 +1,360,000 +98% $13.41 2,747,866 04 Dec 2025 By Fairmount Healthcare Fund II L.P. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBIO Pre-Funded Warrant (Right to Buy) Purchase $1,762,399 +131,434 +8% $13.41 1,768,140 04 Dec 2025 Ordinary Shares 131,434 $0.001000 By Fairmount Healthcare Fund II L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.

Remarks:

Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.